NLRP3 and early-onset autosomal dominant Alzheimer disease: Recent studies showed that two different NLRP3 inhibitors reversed the upregulation of glycolysis in a model of LPS-induced acute neuroinflammation and affected cerebral glucose and lipid metabolism in Alzheimer’s disease model mice [35,36].